Compare Quest Diagnostics Inc (DGX) vs Nano Dimension Ltd - ADR (NNDM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Nano Dimension Ltd - ADR — how do they compare? Quest Diagnostics Inc trades at $230.97 (market cap $25.48B), while Nano Dimension Ltd - ADR trades at $1.55 (market cap $328.52M). The key difference: Quest Diagnostics Inc is far larger — about 77.6× Nano Dimension Ltd - ADR's market cap, and Quest Diagnostics Inc pays a 1.49% dividend while Nano Dimension Ltd - ADR pays none. Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and Nano Dimension Ltd - ADR for 43 Days on average.
| DGX | NNDM | |
|---|---|---|
Market Cap | $25.48B | $328.52M |
Volume | 941,866 | 1,160,945 |
Sector | Health | Technology |
52-Week High | $247.45 | $2.14 |
52-Week Low | $173.49 | $1.21 |
Typical Hold Time | 56 Days | 43 Days |
Enterprise Value | $31.23B | -$76.33M |
Dividend Yield | 1.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $230.97, up 1.75% today, with a technical bias leaning bearish despite recent earnings beats. Revenue grew to $11.04B in 2025, with net income reaching $992M, though profit margins have moderated. Analyst consensus is a $250 price target with a mixed buy/hold sentiment. Recent news highlights growth in consumer testing and partnerships, alongside concerns over potential Medicare reimbursement cuts.
The outlook balances solid fundamentals and growth initiatives against regulatory risks. Upside potential exists from continued operational execution and new ventures like the Apple Health app integration, but investors face headwinds from reimbursement uncertainty and a high debt load. The stock's valuation appears reasonable relative to peers, supporting a cautious but opportunistic view.
Nano Dimension (NNDM) trades at $1.55 with no recent price movement, reflecting a bearish technical signal. The company shows revenue growth from $102M in 2025 to $121M in 2026 but continues to report significant net losses, with a -135.18% net income margin. Recent strategic actions include cost-saving initiatives and leadership changes, with the sale of MarkForged expected to close in late 2026. Cash flow remains volatile, with 2025 showing a net cash outflow of $112M.
The outlook remains challenging due to persistent losses and cash burn, though revenue growth and asset sales provide some stability. Investment opportunities exist if cost reductions translate to profitability, but risks include ongoing operational losses and competitive pressures in the industrial sector. The stock's low valuation multiples may attract value investors, but sustained profitability is needed for long-term upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Nano Dimension Ltd - ADR
Nano Dimension Ltd is engaged in research and development of a three-dimensional printer that prints electronic circuit boards, also known as printed circuit boards, and ink materials and products based on nanotechnology. Its products consist of two main product lines - Dragonfly 2020 3D printer and proprietary ink products. The company's Dragonfly 2020 3D printer currently in development uses proprietary ink and integrated software to quickly create fully functioning PCB prototypes. Geographically, it generates maximum revenue from the USA followed by the Asia Pacific and Europe and Israel. It serves the Commercial, Research and Printing services industries.
Read more on NNDM →
